Chimeric alphavirus vaccine candidates for chikungunya

Eryu Wang, Eugenia Volkova, A. Paige Adams, Naomi Forrester, Shu Yuan Xiao, Ilya Frolov, Scott Weaver

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Chikungunya virus (CHIKV) is an emerging alphavirus that has caused major epidemics in India and islands off the east coast of Africa since 2005. Importations into Europe and the Americas, including one that led to epidemic transmission in Italy during 2007, underscore the risk of endemic establishment elsewhere. Because there is no licensed human vaccine, and an attenuated Investigational New Drug product developed by the U.S. Army causes mild arthritis in some vaccinees, we developed chimeric alphavirus vaccine candidates using either Venezuelan equine encephalitis attenuated vaccine strain TC-83, a naturally attenuated strain of eastern equine encephalitis virus (EEEV), or Sindbis virus as a backbone and the structural protein genes of CHIKV. All vaccine candidates replicated efficiently in cell cultures, and were highly attenuated in mice. All of the chimeras also produced robust neutralizing antibody responses, although the TC-83 and EEEV backbones appeared to offer greater immunogenicity. Vaccinated mice were fully protected against disease and viremia after CHIKV challenge.

Original languageEnglish (US)
Pages (from-to)5030-5039
Number of pages10
JournalVaccine
Volume26
Issue number39
DOIs
StatePublished - Sep 15 2008

Fingerprint

Chikungunya virus
Alphavirus
Eastern equine encephalitis virus
Attenuated Vaccines
Vaccines
vaccines
Venezuelan Equine Encephalomyelitides
Sindbis virus
Investigational Drugs
Sindbis Virus
Eastern Africa
new drugs
chimerism
Viremia
viremia
structural proteins
mice
live vaccines
arthritis
encephalitis

Keywords

  • Alphavirus
  • Arthritis
  • Chikungunya
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Wang, E., Volkova, E., Adams, A. P., Forrester, N., Xiao, S. Y., Frolov, I., & Weaver, S. (2008). Chimeric alphavirus vaccine candidates for chikungunya. Vaccine, 26(39), 5030-5039. https://doi.org/10.1016/j.vaccine.2008.07.054

Chimeric alphavirus vaccine candidates for chikungunya. / Wang, Eryu; Volkova, Eugenia; Adams, A. Paige; Forrester, Naomi; Xiao, Shu Yuan; Frolov, Ilya; Weaver, Scott.

In: Vaccine, Vol. 26, No. 39, 15.09.2008, p. 5030-5039.

Research output: Contribution to journalArticle

Wang, E, Volkova, E, Adams, AP, Forrester, N, Xiao, SY, Frolov, I & Weaver, S 2008, 'Chimeric alphavirus vaccine candidates for chikungunya', Vaccine, vol. 26, no. 39, pp. 5030-5039. https://doi.org/10.1016/j.vaccine.2008.07.054
Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine. 2008 Sep 15;26(39):5030-5039. https://doi.org/10.1016/j.vaccine.2008.07.054
Wang, Eryu ; Volkova, Eugenia ; Adams, A. Paige ; Forrester, Naomi ; Xiao, Shu Yuan ; Frolov, Ilya ; Weaver, Scott. / Chimeric alphavirus vaccine candidates for chikungunya. In: Vaccine. 2008 ; Vol. 26, No. 39. pp. 5030-5039.
@article{d4b4afc3120d4277b65cc3f8c5167d85,
title = "Chimeric alphavirus vaccine candidates for chikungunya",
abstract = "Chikungunya virus (CHIKV) is an emerging alphavirus that has caused major epidemics in India and islands off the east coast of Africa since 2005. Importations into Europe and the Americas, including one that led to epidemic transmission in Italy during 2007, underscore the risk of endemic establishment elsewhere. Because there is no licensed human vaccine, and an attenuated Investigational New Drug product developed by the U.S. Army causes mild arthritis in some vaccinees, we developed chimeric alphavirus vaccine candidates using either Venezuelan equine encephalitis attenuated vaccine strain TC-83, a naturally attenuated strain of eastern equine encephalitis virus (EEEV), or Sindbis virus as a backbone and the structural protein genes of CHIKV. All vaccine candidates replicated efficiently in cell cultures, and were highly attenuated in mice. All of the chimeras also produced robust neutralizing antibody responses, although the TC-83 and EEEV backbones appeared to offer greater immunogenicity. Vaccinated mice were fully protected against disease and viremia after CHIKV challenge.",
keywords = "Alphavirus, Arthritis, Chikungunya, Vaccine",
author = "Eryu Wang and Eugenia Volkova and Adams, {A. Paige} and Naomi Forrester and Xiao, {Shu Yuan} and Ilya Frolov and Scott Weaver",
year = "2008",
month = "9",
day = "15",
doi = "10.1016/j.vaccine.2008.07.054",
language = "English (US)",
volume = "26",
pages = "5030--5039",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "39",

}

TY - JOUR

T1 - Chimeric alphavirus vaccine candidates for chikungunya

AU - Wang, Eryu

AU - Volkova, Eugenia

AU - Adams, A. Paige

AU - Forrester, Naomi

AU - Xiao, Shu Yuan

AU - Frolov, Ilya

AU - Weaver, Scott

PY - 2008/9/15

Y1 - 2008/9/15

N2 - Chikungunya virus (CHIKV) is an emerging alphavirus that has caused major epidemics in India and islands off the east coast of Africa since 2005. Importations into Europe and the Americas, including one that led to epidemic transmission in Italy during 2007, underscore the risk of endemic establishment elsewhere. Because there is no licensed human vaccine, and an attenuated Investigational New Drug product developed by the U.S. Army causes mild arthritis in some vaccinees, we developed chimeric alphavirus vaccine candidates using either Venezuelan equine encephalitis attenuated vaccine strain TC-83, a naturally attenuated strain of eastern equine encephalitis virus (EEEV), or Sindbis virus as a backbone and the structural protein genes of CHIKV. All vaccine candidates replicated efficiently in cell cultures, and were highly attenuated in mice. All of the chimeras also produced robust neutralizing antibody responses, although the TC-83 and EEEV backbones appeared to offer greater immunogenicity. Vaccinated mice were fully protected against disease and viremia after CHIKV challenge.

AB - Chikungunya virus (CHIKV) is an emerging alphavirus that has caused major epidemics in India and islands off the east coast of Africa since 2005. Importations into Europe and the Americas, including one that led to epidemic transmission in Italy during 2007, underscore the risk of endemic establishment elsewhere. Because there is no licensed human vaccine, and an attenuated Investigational New Drug product developed by the U.S. Army causes mild arthritis in some vaccinees, we developed chimeric alphavirus vaccine candidates using either Venezuelan equine encephalitis attenuated vaccine strain TC-83, a naturally attenuated strain of eastern equine encephalitis virus (EEEV), or Sindbis virus as a backbone and the structural protein genes of CHIKV. All vaccine candidates replicated efficiently in cell cultures, and were highly attenuated in mice. All of the chimeras also produced robust neutralizing antibody responses, although the TC-83 and EEEV backbones appeared to offer greater immunogenicity. Vaccinated mice were fully protected against disease and viremia after CHIKV challenge.

KW - Alphavirus

KW - Arthritis

KW - Chikungunya

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=50549090749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50549090749&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.07.054

DO - 10.1016/j.vaccine.2008.07.054

M3 - Article

VL - 26

SP - 5030

EP - 5039

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 39

ER -